Choi WS, et al. – Researchers compared NBP608 with Zostavax in terms of immunogenicity and safety in healthy adults aged 50 years or older enrolled in this multicenter, randomized, double-blinded, active-controlled, parallel-group clinical trial. The screening included 845 subjects, among whom 413 (NBP608 group) and 411 (comparator group) received vaccination. At 6 weeks following vaccination, the interferon-γ and interleukin-2 enzyme-linked immunosorbent spot assays-determined geometric mean spot numbers did not differ statistically significantly between the two groups. The incidence of adverse events within 6 weeks following vaccination was 49.82%, 50.73% in the NBP608 group, and 48.91% in the comparator group. With regard to immunogenicity, NBP608 was found to be non-inferior to Zostavax. Furthermore, administration of NBP608 to adults aged 50 years or older was safe in this study.